Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The 'New' Vifor Pharma: Focused On Specialty Pharma

Executive Summary

With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.

You may also be interested in...



Going Solo Suits Vifor And Its Hopes For Two Blockbusters

Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.

AstraZeneca's Lokelma To Join Veltassa In Hyperkalemia Sector

The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.

Pipeline Watch: Phase III Starts With Rimegepant, ARQ087 And SGX942

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel